Market Overview

UPDATE: Morgan Stanley Reiterates on Pfizer as Vaccine Pipeline is Under-Appreciated

Share:
Related PFE
Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More
3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise
Stock Futures Rise; Adobe, Costco Gain As Top Railroad Sells Off (Investor's Business Daily)

In a report published Friday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Pfizer (NYSE: PFE), and raised the price target from $34.00 to $36.00.

In the report, Morgan Stanley noted, “We believe Pfizer can outperform the pharma group given its potential for positive pipeline news and strategic action. Mgmt is committed to share repurchase and dividend increases. Financial and strategic action should continue to drive shareholder value.”

Pfizer closed on Thursday at $31.12.

Latest Ratings for PFE

DateFirmActionFromTo
Oct 2017BMO CapitalMaintainsOutperform
Sep 2017Morgan StanleyUpgradesEqual-WeightOverweight
Aug 2017BMO CapitalUpgradesMarket PerformOutperform

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!